Dyadic to Present at Two Upcoming Investor Conferences

February 25, 2019 10:35 AM

JUPITER, FL / ACCESSWIRE / February 25, 2019 / Dyadic International, Inc. (the ''Company'') (OTCQX: DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb, will be presenting at the following two upcoming investor conferences:SVB Leerink Global Healthcare Conference New York City, NYWednesday, February 27, 2019 3:30 p.m. ET31st Annual ROTH ConferenceThe Ritz Carlton, Laguna NiguelDana Point, CAPanel...

Read more

Scientific Analyses Confirm Important Benefits from Processing CBD Oil with Pressure BioSciences' Proprietary Ultra Shear Technology Platform

February 21, 2019 9:22 AM

Laboratory Testing Shows UST-Prepared CBD Oil Solutions Meet Challenging Nanoemulsion Specifications and Exhibit Minimal CBD Loss During Processing SOUTH EASTON, MA / ACCESSWIRE / February 21, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries. The...

Read more

Qrons Retains Investment Banking Firm Network1 Financial Securities Inc.

February 21, 2019 9:00 AM

Mandate includes Advisory, Capital Raising and Uplisting Guidance MIAMI, FL / ACCESSWIRE / February 21, 2019 / Qrons Inc. (OTC PINK: QRON) ("Qrons" or the "Company"), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel- based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries ("TBIs"), both concussions and penetrating injuries , announced today that it has retained...

Read more

Dyadic Announces Effectiveness of Form 10 Registration Statement and Application to NASDAQ

February 13, 2019 12:10 PM

JUPITER, FL / ACCESSWIRE / February 13, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI) today announced that the Securities and Exchange Commission (the "SEC") has declared the Company's Registration Statement on Form 10-12G (the "Form 10") effective as of February 12, 2019. As a result, the Company is now subject to the periodic and current reporting requirements of Section 13(a) of the Securities and Exchange Act of 1934.A copy...

Read more

Pressure BioSciences Makes CBD Oil Water Soluble, Offering Solution to CBD Absorption Issue in Food & Beverages

February 13, 2019 8:15 AM

New Video Demonstrates PBI's Ultra Shear Technology and Potential Impact in CBD, Nutraceuticals, Foods, Cosmetics, and Other Oil-Based Markets SOUTH EASTON, MA / ACCESSWIRE / February 13, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (''PBI'' and the ''Company''), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today...

Read more

Viridium to Resume Trading February 13 2019

February 11, 2019 6:35 PM

VANCOUVER, BC / ACCESSWIRE / February 11, 2019 / Viridium Pacific Group Ltd. ("Viridium") (TSXV: VIR) (OTCPink: VIRFF) wishes to advise, upon inquiry by Viridium, the TSX Venture Exchange has confirmed that the trading halt imposed on Viridium's common shares will be lifted at market open on Wednesday, February 13, 2019 (not February 11, 2019 as originally conveyed). The trading halt was a requirement by the TSX Venture Exchange in connection...

Read more

Molecular Partners Reports Key Financials for FY 2018 and Corporate Highlights for Q4 2018: Company Positioned for Growth Following Positive Phase 3 Abicipar Data and Validation of Darpin (R) Platform Through Amgen Collaboration

February 7, 2019 1:00 AM

Research & Development: MP0310: Molecular Partners and Amgen announced strategic collaboration for clinical development and commercialization of lead IO candidate MP0310 (FAP x 4-1BB), validating the company's immuno-oncology toolbox and DARPin® platform; first-in-human trial planned for H2 2019 MP0250 and MP0274: Additional patient data of ongoing phase 2 trial of MP0250 in combination with...

Read more

HemaGenetics Announces Completion of the Plan of Arrangement with 1169077 BC Ltd.

February 6, 2019 3:55 PM

VANCOUVER, BC / ACCESSWIRE / February 6, 2019 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that further to the previously announced arrangement under the arrangement agreement entered into on June 26, 2018 between the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169029 B.C. Ltd., 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and 1169082 B.C. Ltd. (the "Arrangement"), the...

Read more

HemaGenetics Announces Completion of the Plan of Arrangement with 1169071 BC Ltd.

February 6, 2019 3:53 PM

VANCOUVER, BC / ACCESSWIRE / February 6, 2019 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that further to the previously announced arrangement under the arrangement agreement entered into on June 26, 2018 between the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169029 B.C. Ltd., 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and 1169082 B.C. Ltd. (the "Arrangement"), the...

Read more

Pressure BioSciences, Inc and NutraFuels, Inc to Collaborate on the Development of Water-Soluble Nanoemulsion-based Nutraceuticals

January 30, 2019 9:15 AM

Primary Goal is to Optimize PBI's UST Platform for the Development and Manufacture of the Next Generation of New and Improved Nutraceutical and Other Large Market Emulsion-based Products, Such as Cosmetics and Pharmaceuticals. SOUTH EASTON, MA / ACCESSWIRE / January 30, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) and NutraFuels, Inc. (OTCQB: NTFU) (together, the ''Companies'') today announced a collaboration to advance the development of a...

Read more

Qrons Completes Successful In-Vivo Experiment with its QS100 Candidate Product for Treating Penetrating Brain Injuries in an Animal Model

January 30, 2019 9:00 AM

Detailed experimental results were filed in a second provisional patent application for "Techniques for Promoting Neuronal Recovery." Preparing for animal In-vivo efficacy experiments with its QS200™ Candidate Product for treating Concussions and other Diffused Axonal Injuries. MIAMI, FL / ACCESSWIRE / January 30, 2019 / Qrons Inc. (OTC PINK: QRON) ("Qrons "or the "Company"), a preclinical biotechnology company developing advanced stem...

Read more

Vitro Biopharma 2018 CEO Shareholder Letter: Record Revenues from Stem Cell Treatments

January 24, 2019 4:00 PM

Record Revenues from Stem Cell Treatments Lead to 4th Quarter Break even Cash flow & Growth Continues in Early 2019 GOLDEN, CO / ACCESSWIRE / January 24, 2019 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its CEO letter to its shareholders including discussion of its 2018 results of operations ended October 31st 2018 and its expansion plans for 2019. Dear Shareholders, In 2017-2018 we achieved: Increased...

Read more

Dyadic International Named to 2019 OTCQX Best 50

January 24, 2019 1:15 PM

JUPITER, FL / ACCESSWIRE / January 24, 2019 / Dyadic International, Inc. ("Dyadic" or "the Company") (OTCQX: DYAI) is pleased to announce it has been named to the 2019 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year.The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX market. The ranking is calculated based on an equal weighting of one-year...

Read more

Record Number of Scientific Papers Citing the Significant Benefits of Pressure BioSciences' PCT Platform Published in 2018

January 24, 2019 9:28 AM

Over 20 Journal Articles Describe the Advantages of the PCT Platform in Multiple Areas of Research, Including Cancer, Biomarker Discovery, and Food Safety SOUTH EASTON, MA / ACCESSWIRE / January 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries,...

Read more

HemaGenetics Announces Completion of the Plan of Arrangement with 1169029 B.C. Ltd.

January 22, 2019 6:20 PM

VANCOUVER, BC / ACCESSWIRE / January 22, 2019 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that further to the previously announced arrangement under the arrangement agreement entered into on June 26, 2018 between the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169029 B.C. Ltd., 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and 1169082 B.C. Ltd. (the "Arrangement"), the Company...

Read more

1169029 B.C. Ltd. Announces Completion of the Arrangement with HemaGenetics Technologies Corp. and Issuance of Shares in Furtherance of the Arrangement

January 22, 2019 6:20 PM

VANCOUVER, BC / ACCESSWIRE / January 22, 2019 / 1169029 B.C. Ltd. (the "Company") is pleased to announce that as a result of the completion of a plan of arrangement between the Company and HemaGenetics Technologies Corp. ("HGT") under the arrangement agreement entered into on June 26, 2018 between HGT, the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and...

Read more

Dyadic to Present at NobleCon XV

January 22, 2019 10:00 AM

JUPITER, FL / ACCESSWIRE / January 22, 2019 / Dyadic International, Inc. (the ''Company'') (OTCQX: DYAI) today announced that its CEO, Mark Emalfarb will present at NobleConXV - Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Monday, January 28, 12:30 pm Eastern Standard Time.A high-definition, video webcast of the presentation will be available the following day on the Company's website...

Read more

HemaGenetics Announces Setting of the Effective Date & Record Date for the Plan of Arrangement with 1169029 B.C. Ltd.

January 18, 2019 1:57 PM

VANCOUVER, BC / ACCESSWIRE / January 18, 2019 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that further to the previously announced arrangement under the arrangement agreement entered into on June 26, 2018 between the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169029 B.C. Ltd., 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and 1169082 B.C. Ltd. (the "Arrangement"), the Company has...

Read more

Dyadic Announces the Filing of Replacement Form 10 Registration Statement with SEC

January 15, 2019 8:40 AM

JUPITER, FL / ACCESSWIRE / January 15, 2019 / Dyadic International, Inc. (the "Company") ("OTCQX: DYAI) today announced that the Company has filed a replacement Registration Statement on Form 10-12G (the "Replacement Form 10") with the Securities and Exchange Commission (the "Commission").On November 5, 2018, the Company filed its initial Form 10-12G (File No. 000-55264) (the "Initial Form 10"), which was withdrawn on January 2, 2019 in order to...

Read more

Quanta Launches Proprietary Polarized CBD Product Lines

January 10, 2019 8:30 AM

Company discontinues licensing to CBD brands, sees larger upside in manufacturing its own product lines LOS ANGELES, CA / ACCESSWIRE / January 10, 2019 / Quanta, Inc. (OTC PINK: QNTA) an applied science company, focused on enhancing energy levels in plant matter, including hemp and cannabis, to increase performance within the human body, today announced that it will begin manufacturing its own line of polarized cannabidiol (CBD) products due to...

Read more